drug development

Integrating scientific and engineering expertise is critical for enabling faster, more cost-effective drug discovery. 

What’s stopping major progress in the development of new drugs right now? Biotech leaders and researchers shared their thoughts.

QurAlis researchers have developed QRL-101, a new drug candidate that targets overactive neurons to prevent cell death in ALS.  

Michelle Werner and her team at Alltrna are developing novel tRNA therapeutics to overwrite mutations shared by hundreds of rare genetic diseases.

Xaira Therapeutics is leveraging novel generative AI models to design medicines for diseases without treatments.

As scientific output grows, the risk of a promising drug getting lost increases, but advances in artificial intelligence and machine learning may prevent that.

The new complex is inexpensive to produce, and its unique architecture makes chemical reactions integral to drug discovery more stable and efficient.

Elizabeth Laws leads Sanofi’s inflammation and immunology development pipeline to test the first oral TNFR1 inhibitor for rheumatoid arthritis and psoriasis.

Merck researchers developed an effective vaccine against pneumococcal diseases.

Manish Sharma led a clinical trial for a new antibody-drug conjugate that decreased tumor size in patients who had not responded to chemotherapy.